Doctronic
Doctronic has created an AI-powered symptom-checker and communication tool that guides patients on likely conditions and next steps (self-care vs. seeing a doctor). Distributed direct-to-consumer and through employers, insurers, and providers; monetized via per-use fees and enterprise contracts.
Industry
Challenge
Most state medical practice acts were written before AI existed. They often require synchronous physician-patient relationship, a physician exam before prescribing, and a licensed physician as the source of any prescription. Doctronic's model threads this needle but lacked explicit statutory or regulatory authorization in the vast majority of states.
Execution
Tusk built a state-by-state legalization strategy, starting with Utah, where we helped secure a first-of-its-kind regulatory waiver with the state's Office of Artificial Intelligence Policy.
That agreement launched the nation's first state-authorized AI prescription renewal program in January 2026, backed by a physician-review structure that produced 97% AI-physician concordance and zero adverse events.
We used that Utah proof point as the template for active legislative and regulatory campaigns in Wyoming, West Virginia, North Carolina, Texas, Ohio, Arizona, Tennessee, and Los Angeles County, coordinating state lobbyists in each market while running a parallel FDA strategy.
Outcome
Since Tusk began working with Doctronic as both investor and regulatory advisor, the company launched the first state-authorized AI prescription renewal program in the country, built an active legislative and regulatory pipeline across eight additional states, and closed both a $25M Series A (September 2025) and a $40M Series B (February 2026) at a $300M valuation, co-led by Abstract Ventures and Lightspeed.
